July 2026 Highlights Advances in Pain Management, Opioid Research, and Emerging Treatment Strategies
July 2026 marked an important month for pain management, with several notable developments spanning acute pain treatment, chronic pain care, opioid stewardship, and pharmaceutical innovation. New medications, encouraging clinical trial results, and evolving research continued to shape the future of pain management, while reinforcing the growing emphasis on personalized, evidence-based care.
Among the month's most significant milestones was the introduction of the first over-the-counter fixed-dose combination of acetaminophen and naproxen sodium, providing consumers with an additional non-prescription option for managing short-term pain. Researchers also reported promising Phase 2b clinical trial results for a selective NaV1.8 inhibitor, highlighting the potential of targeted, non-opioid therapies designed to interrupt pain signaling without the risks associated with traditional opioid medications. In addition, the U.S. Food and Drug Administration (FDA) cleared an investigational extended-release formulation of nefopam, further expanding the pipeline of innovative pain treatments currently under development.
Research published throughout the month also provided new insights into opioid prescribing and long-term pain management. Investigators examined how patients use opioids following episodes of acute pain, offering a clearer understanding of prescribing patterns and potential opportunities to reduce unnecessary long-term exposure. Other studies evaluated patient-centered opioid tapering strategies, demonstrating the importance of individualized approaches that help patients safely reduce long-term opioid therapy while maintaining effective pain control and quality of life.
Evidence supporting multimodal pain management also continued to grow. New findings reinforced the benefits of combining multiple treatment approaches—including medications, non-pharmacologic therapies, and individualized care plans—to improve pain relief in procedural settings and for patients receiving cancer-related pain treatment. These strategies aim to maximize effectiveness while minimizing reliance on opioid medications whenever appropriate.
At the same time, several developments highlighted ongoing challenges facing clinicians, pharmacists, and healthcare systems. Real-world prescribing data indicated that suzetrigine (Journavx), developed by Vertex Pharmaceuticals, is already being used outside its FDA-approved indication for acute pain management. While off-label prescribing is common in clinical practice, the findings underscore the need for continued monitoring, additional research, and careful evaluation of safety and effectiveness in broader patient populations.
Meanwhile, advances in genetic research provided stronger evidence that fibromyalgia has identifiable biological underpinnings, helping move the condition further away from misconceptions that it lacks a physical basis. Although these discoveries improve scientific understanding of the disorder, researchers caution that they have not yet produced a reliable diagnostic test or led directly to new targeted treatments.
Taken together, the developments reported throughout July illustrate the continued shift toward mechanism-based, precision pain management, with increasing focus on therapies that address the underlying biology of pain rather than relying primarily on opioid medications. At the same time, they highlight the ongoing need to balance innovation with medication safety, responsible opioid prescribing, equitable patient access, and the careful translation of emerging scientific evidence into everyday clinical practice. As research continues to evolve, healthcare professionals will play a critical role in integrating these advances while ensuring patients receive safe, individualized, and effective pain care.
Source: Pharmacy Times